ABOUT US

Our Mission

Turnstone Biologics’ mission is to deliver breakthrough viral immunotherapies to improve survival for patients with cancer.

Turnstone Biologics is a privately-held immuno-oncology company based in Ottawa, Ontario, and New York. Since 2015, we have raised $50 million in venture capital financing, brought in more than $100 million in non-dilutive funding, and have received numerous biotechnology industry awards, including being named a 2017 Fierce 15 company.

 

Our scientific founders, Drs. John Bell, David Stojdl and Brian Lichty, are world leaders in the oncolytic virus and immunotherapy field. Collectively, they have published more than 200 publications in leading journals, and have spent years engineering and developing viruses to create the next generation of powerful, targeted therapies for cancer patients.

 

Our passionate team of leaders in oncology has decades of experience in biotechnology, academia and pharmaceutical drug development. With comprehensive capabilities in immuno-oncology discovery, basic research, translation, clinical development, manufacturing, and commercialization, we are committed to bringing new medicines to people with cancer to improve their lives.

 

our science

Breakthrough Viral Immunotherapies

Turnstone Biologics is the sole company developing viral immunotherapies that drive benefit through simultaneous generation of targeted immune responses and modulation of the tumor environment.

The Maraba Virus

Turnstone Biologics’ founders screened hundreds of viruses before discovering that Maraba, a single-stranded RNA virus isolated from sand flies around the Maraba region of Brazil, was an optimal platform for cancer therapeutics. Maraba was engineered to MG1 to optimize its safety, selectivity, manufacturability and potency to kill tumor cells, and transgene capacity was added for targeted expression of tumor-associated antigens and immunomodulatory agents.

MG1: The First 2-In-1 Approach

Our engineered oncolytic Maraba virus, known as MG1, is the first therapeutic 2-in-1 approach to combine an oncolytic virus and an antigen-specific cancer vaccine. With its unprecedented dual-mechanism driving robust killer T cell responses and disrupting the tumor microenvironment, MG1 kills cancer cells at metastatic sites throughout the body, and generates a durable immune response resulting in long-term memory to prevent recurrence.

our pipeline

Driven by Science and Innovation

At Turnstone Biologics, we are science-driven: science informs our research, clinical development and approach for patients. We have developed a robust pipeline of new medicines for multiple solid tumors.

Our first program is an engineered Maraba virus (MG1) that expresses the tumor-associated antigen MAGEA3, which is highly expressed on many different types of solid tumors. We are evaluating this therapy in patients with non-small cell lung cancer (NSCLC), breast cancer and esophageal cancer in two clinical trials – alone and in combination with the anti-PD-1 checkpoint inhibitor Keytruda™. We expect to begin human studies with our second MG1 therapy for patients with human papillomavirus (HPV) positive tumors in 2018, and have multiple other viral immunotherapies in development.

 

Program Pipeline

For more information about the MAGEA3 monotherapy trial click here and the MAGEA3 and anti-PD-1 combination trial click here.

our team

Leadership

Turnstone Biologics was founded by world-leading experts in oncolytic viruses and immunotherapies who have defined and advanced the field over the course of multiple decades. Our leadership team includes experts from academia and the life sciences industry who share the vision of bringing innovative viral immunotherapies based on our unique oncolytic Maraba virus platform to patients.

close
Sammy Farah, Ph.D., M.B.A.

Sammy Farah, Ph.D., M.B.A.

President and Chief Executive Officer

Dr. Sammy Farah has extensive vaccine expertise and almost 20 years of scientific, business and executive management experience in the biotechnology industry. He joined Turnstone Biologics from Synthetic Genomics Vaccines, Inc., where he served as President. Prior to that, he was Chief Business Officer of Immune Design Corp. And before then, Sammy was at Versant Ventures where he specialized in biotechnology investing and new company formation, and at Merck & Co., Inc. where he led technology support for multiple commercial vaccine franchises before joining the business development and licensing group to evaluate and execute new external technology and research partnerships. Dr. Farah earned an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in biochemical engineering from Stanford University, and a B.S. in biochemical engineering from the Massachusetts Institute of Technology.

close
Mike Burgess, MBChB, Ph.D.

Mike Burgess, MBChB, Ph.D.

President of R&D

Dr. Mike Burgess brings 20 years of drug research and development experience to Turnstone Biologics. At Bristol-Myers Squibb, he led strategy and execution of translational medicine, early-stage clinical trials and clinical pharmacology across all therapeutic areas, including oncology. Prior to this at Roche, Mike held several different senior leadership positions, including acting global head of Roche Pharma Research and Early Development (pRED) and Senior Vice President and Global Head of Oncology Research and Early Development. Before joining Roche, Mike spent 7 years at Lilly working on early stage oncology trials. Mike received his medical degree (MBChB) and a Ph.D. in molecular biology from the University of Bristol, UK and spent 10 years as a practicing physician in pediatrics and pediatric oncology.

close
Kris Elverum, M.B.A.

Kris Elverum, M.B.A.

Chief Business Officer

Kris Elverum has more than 12 years of experience in the pharmaceutical/biotech industry, with expertise in corporate strategy, business development, commercial and operations. He joined Turnstone Biologics from SQZ Biotech, a pre-clinical stage biotechnology company developing cell therapies, where he was Chief Business Officer. Prior to that, he led the U.S. commercial model for CTL019, Novartis’ breakthrough CAR-T cell therapy, and other CAR-T cell immunotherapies. Earlier in his career, he held various commercial roles for Novartis Pharmaceuticals and served as Global Head of Strategy for Sandoz. Before that, he was an Engagement Manager with McKinsey & Co. where he served clients across the healthcare value chain. Kris earned an M.B.A. and a B.S. from the University of Minnesota’s Carlson School of Management.

close
Brian Lichty, Ph.D.

Brian Lichty, Ph.D.

Senior Vice President, Basic Research

Dr. Brian Lichty is a distinguished scientist with extensive expertise in oncolytic viruses and related immunotherapies, including seminal work with Dr. John Bell at the Ottawa Regional Cancer Centre. He is a professor in the Department of Pathology & Molecular Medicine and the McMaster Immunology Research Centre (MIRC) at McMaster University. Dr. Lichty’s expertise includes influence research in the identification of strategies to leverage oncolytic viruses to harness the patient’s immune system in a sustainable manner, including vaccine design and engineering to directly engage the adaptive immune system tumor-specific and/or to enhance combinations with other immunotherapies. He is also director of the Robert E. Fitzhenry vector lab at McMaster University where clinical-grade viral vaccines are manufactured for human clinical trials. Dr. Lichty earned a Ph.D. from the University of Toronto and a B.Sc. from the University of Guelph.

close
José Manuel Otero, Ph.D.

José Manuel Otero, Ph.D.

Vice President, Manufacturing & CMC

Dr. José Manuel (Manny) Otero has 15 years of experience in the biopharmaceutical industry, including in bioprocess development, manufacturing, and CMC of vaccines and complex biologics. He joined Turnstone Biologics from Seres Therapeutics, Inc., a leader in human microbiome therapeutics, where he was Vice President of Bioprocess Development and Manufacturing. At Seres Therapeutics, Dr. Otero oversaw the expansion of the bioprocess development and manufacturing group, and was the corporate team leader for the first synthetic microbiome therapeutic to enter Phase 1b clinical studies in the United States. Prior to that, Dr. Otero was Director of Engineering at Merck & Co.’s Vaccine Manufacturing Sciences & Commercialization division. In that role, he supported development programs for the Varivax™, Zostavax™, ProQuad™, and MMRII™ franchises. Prior to that role, he was Head of Fermentation Process Development, Vaccine Process Development within Merck Research Labs. Dr. Otero has authored more than 20 peer-reviewed publications. He earned a Ph.D. in chemical and biological engineering from Chalmers University of Technology in Gothenburg, Sweden, and an M.Eng. in biomedical engineering and a B.S. in chemical engineering from the Massachusetts Institute of Technology.

close
Maura Campbell, Ph.D.

Maura Campbell, Ph.D.

Vice President, Corporate Affairs

Dr. Maura Campbell has spent more than 20 years in technology transfer and the management and commercialization of intellectual property (IP). She has business management experience in all key sectors of biotech, including private and public companies, universities and research institutes, and government-funded public sector research organizations (National Centre of Excellence [NCE]). Maura joined Turnstone Biologics from VBI Vaccines where she served as Director, Intellectual Property. She also was with the Ottawa Hospital Research Institute (OHRI) as a Senior Research Program Manager, where she oversaw the oncolytic vaccine project commercialization. Earlier in her career, Maura was the Director of Intellectual Property for PainCeptor Pharma Corporation, the Manager of Technology Transfer & Commercialization for the OHRI, and the Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems at NCE. She has served as an IP consultant to a number of Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC and Sussex Research Labs. Maura received a Ph.D. in biochemistry from the University of Ottawa, and an M.Sc. and a B.Sc. in biochemistry from Queen’s University in Kingston.

close
Caroline Breitbach, Ph.D.

Caroline Breitbach, Ph.D.

Vice President, Translational Development

Dr. Caroline Breitbach joined Turnstone Biologics from SillaJen Biotherapeutics (formerly Jennerex) where she was Vice President, Clinical and Translational Research. In that position, she oversaw translational and early-stage clinical development of an oncolytic immunotherapy and contributed to lead candidate development from Phase 1 through initiation of Phase 3 evaluation. Previously, she worked in Dr. John Bell’s group at the University of Ottawa, where she evaluated acute effects of oncolytic viruses on the tumor immune microenvironment. She earned a Ph.D. in biochemistry from the University of Ottawa and an Honor’s B.Sc. in microbiology and immunology from McGill University.

close
John Bell, Ph.D.

John Bell, Ph.D.

Ottawa Hospital Research Institute

Dr. John Bell began his independent research career at McGill University before moving to the University of Ottawa and becoming a professor in the Department of Medicine. He is a member of the Center for Innovative Cancer Therapeutics at The Ottawa Hospital Cancer Center and a Senior Scientist at the Ottawa Hospital Research Institute. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox-funded group from across Canada that is developing virus-based cancer therapeutics, and is the Director of the Biotherapeutics Program at the Ontario Institute for Cancer Research. John is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and a Fellow of the Royal Society of Canada. Dr. Bell received a Ph.D. from McMaster University and then trained at the Medical Research Council in London, U.K.

close
Brian Lichty, Ph.D.

Brian Lichty, Ph.D.

McMaster University

Dr. Brian Lichty is a distinguished scientist with extensive expertise in oncolytic viruses and related immunotherapies, including seminal work with Dr. John Bell at the Ottawa Regional Cancer Centre. He is a professor in the Department of Pathology & Molecular Medicine and the McMaster Immunology Research Centre (MIRC) at McMaster University. Dr. Lichty’s expertise includes influence research in the identification of strategies to leverage oncolytic viruses to harness the patient’s immune system in a sustainable manner, including vaccine design and engineering to directly engage the adaptive immune system tumor-specific and/or to enhance combinations with other immunotherapies. He is also director of the Robert E. Fitzhenry vector lab at McMaster University where clinical-grade viral vaccines are manufactured for human clinical trials. Dr. Lichty earned a Ph.D. from the University of Toronto and a B.Sc. from the University of Guelph.

close
David Stojdl, Ph.D.

David Stojdl, Ph.D.

University of Ottawa

Dr. David Stojdl pioneered the exploration of host-virus interactions critical to oncolytic therapy to guide the clinical development of more effective virus platforms. At the Ottawa Regional Cancer Centre, he first identified VSV as an oncolytic virus and defined the archetypal role of interferon signaling in tumor-specific oncolytic virus targeting. Since joining the CHEO Research Institute in 2004, Dr. Stojdl has discovered and developed several novel oncolytic vector platforms, including the Maraba oncolytic virus platform. Dr. Stojdl also directs the CHEO Automated Screening Centre (CASC), leveraging state-of-the-art high-throughput robotic screening technology to uncover new insights for the clinical development of oncolytic virus biotherapies. Dr. Stojdl is a professor in the Department of Pediatrics and Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. He was a scientific co-founder and consultant to Jennerex Biotherapeutics (later acquired by SillaJen Biotherapeutics). He received a Ph.D. from the University of Ottawa and an M.S. and B.S. in microbiology and immunology from the University of Western Ontario.

close
Brad Bolzon, Ph.D.

Brad Bolzon, Ph.D.


Dr. Brad Bolzon is a Managing Director at Versant Ventures and on the biotech investment team. He has more than 13 years of global pharmaceutical industry experience. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances for F. Hoffmann-La Roche. Under his leadership, Roche established alliances with more than 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.

close
Jerel Davis, Ph.D.

Jerel Davis, Ph.D.


Dr. Jerel Davis is a Managing Director at Versant Ventures and is based in Vancouver. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups. He has also led Versant’s execution of build-to-buy structured acquisitions with Celgene, Roche and Bayer. Over the last few years, Jerel has focused on establishing Versant’s presence in Canada, including the launch of new companies in Vancouver, Toronto and Montreal. Prior to joining Versant, Jerel was Associate Principal at McKinsey and Company where he advised pharmaceutical, biotechnology, medical device and molecular diagnostics companies. He has worked in a number of healthcare markets globally including the United States, Europe, China, Russia and India. Jerel was a post-doctoral researcher at Stanford University and worked in research at Amgen.

close
Rishi Gupta, J.D.

Rishi Gupta, J.D.


Rishi Gupta is a private equity partner at OrbiMed. Prior to that, he was a healthcare investment banker at Raymond James & Associates, served as manager of corporate development at Veritas Medicine and was a summer associate at Wachtell, Lipton, Rosen & Katz. Rishi has published scientific articles on the mechanisms of HIV entry into host cells and legal articles on intellectual property laws in the developing world. In addition to Turnstone Biologics, he serves or has served on the boards of Dimension Therapeutics, Symbiomix Therapeutics, Avitide, Verona Pharma, ChemoCentryx and Sientra. He has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, Biotie, Invitae and ORIC Pharmaceuticals. Rishi earned a J.D. from the Yale Law School and an A.B. degree magna cum laude in biochemical sciences from Harvard College.

close
Ben Auspitz

Ben Auspitz


Ben Auspitz is a Partner at F-Prime Capital and has worked in the pharmaceutical and life science industry for more than 20 years, both as a consultant and investor. Before joining F-Prime Capital, he served as Therapeutic Area Head for immuno-inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In that role, he oversaw the advancement of seven programs from assay stage into Phase 2 clinical studies, and was co-inventor on 15 product patents. Ben focuses on therapeutics and has a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, and two companies for which he was a company founder, Orchard Therapeutics and Dimension Therapeutics. He currently serves on the board of directors of Unum Therapeutics, Precision Biosciences, Orchard Therapeutics, Symbiomix Pharmaceuticals and Compass Therapeutics. Previously, Ben was involved in F-Prime Capital investments in Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Blueprint Medicine (NASDAQ: BPMC), Coherus Biosciences (NASDAQ: CHRS), REGENXBio (NASDAQ: RGNX), Dimension Therapeutics (NASDAQ:DMTX), and Ultragenyx (NASDAQ: RARE). He received a B.A. from Harvard University.

close
David O’Neill, Ph.D.

David O’Neill, Ph.D.


David O’Neill brings extensive experience in Pharma and biotech to his role as Acting President of FACIT.  FACIT is the commercialization partner of the Ontario Institute for Cancer Research and an active seed stage investor.  Dr. O’Neill has a wealth of networks and transaction experience through various business development roles at AstraZeneca, Ambit Biosciences (Daiichi Sankyo), Kinomescan (Discoverx/Eurofins), Fluorinov Pharma (Trillium Therapeutics).  He also held operational roles including non-clinical safety, IND submission and Project Leader during clinical development of Quizartinib.  He has provided interim executive management to FACIT spin outs Turnstone, Propellon and Novera Therapeutics. In addition to serving on the Board of Turnstone, he is also a Board Observer for Fusion Pharmaceuticals.  Dr. O’Neill holds a Ph.D from Western University from the Faculty of Health Sciences with an emphasis on heat shock protein biology.

close
Sammy Farah, Ph.D. M.B.A.

Sammy Farah, Ph.D. M.B.A.


Dr. Sammy Farah has extensive vaccine expertise and almost 20 years of scientific, business and executive management experience in the biotechnology industry. He joined Turnstone Biologics from Synthetic Genomics Vaccines, Inc., where he served as President. Prior to that, he was Chief Business Officer of Immune Design Corp. And before then, Sammy was at Versant Ventures where he specialized in biotechnology investing and new company formation, and at Merck & Co., Inc. where he led technology support for multiple commercial vaccine franchises before joining the business development and licensing group to evaluate and execute new external technology and research partnerships. Dr. Farah earned an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in biochemical engineering from Stanford University, and a B.S. in biochemical engineering from the Massachusetts Institute of Technology.

close
John Bell, Ph.D.

John Bell, Ph.D.


Dr. John Bell began his independent research career at McGill University before moving to the University of Ottawa and becoming a professor in the Department of Medicine. He is a member of the Center for Innovative Cancer Therapeutics at The Ottawa Hospital Cancer Center and a Senior Scientist at the Ottawa Hospital Research Institute. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox-funded group from across Canada that is developing virus-based cancer therapeutics, and is the Director of the Biotherapeutics Program at the Ontario Institute for Cancer Research. John is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and a Fellow of the Royal Society of Canada. Dr. Bell received a Ph.D. from McMaster University and then trained at the Medical Research Council in London, U.K.

close
Jeff Courtney

Jeff Courtney

In Memoriam

Jeff Courtney helped to form Turnstone Biologics and was an outstanding leader for FACIT (Fight Against Cancer Innovation Trust). Jeff’s life’s work and warm personality inspires all of us at Turnstone Biologics to drive forward our mission to help cancer patients, and we greatly miss his presence, leadership and friendship.

We are backed by top-tier investors who are committed to the company’s growth. We have raised approximately $50 million in venture capital financing since our inception.

Turnstone Biologics views strategic partnerships as a core component of our strategy and is interested in collaborating with biopharma companies, academic centers, and universities to transform patient care.

In the fall of 2017, Turnstone Biologics entered into a strategic research, option and license agreement with AbbVie for our Ad-MG1-MAGEA3 therapy and two research-stage candidates that are presently in development.

Careers

Turnstone Biologics’ team works with a sense of urgency to fulfill our mission. Our decision-making is driven by science and our therapeutics are designed with the patient in mind.

We value transparency, innovation, integrity and purpose as we collaborate to transform cancer care. If you’re a passionate person, and our mission and science excite you, Turnstone Biologics might be for you.

Team Member Openings

Turnstone Biologics is dedicated to excellence and innovation in every aspect of our science and business. We are actively looking for exceptional individuals who share our passion for developing and delivering next-generation viral immunotherapies. We offer competitive compensation and benefits and are an equal opportunity employer.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency.  Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:

Reporting to a Group Leader/Sr. Scientist in Ottawa, the position of Research Technician is responsible for supporting the generation of novel oncolytic vaccine constructs to contribute to Turnstone Biologics growing pre-clinical pipeline.

Our company’s technology is based around replicating oncolytic virus vaccines engineered to target tumours and launch massive tumour targeting immune responses.  The core of this technology lies in the designing and building of these genetically constructed viruses.  Your role will be to join a team of molecular biologists who engineer these nanomedicines for preclinical and clinical development.  There will be additional opportunities to work with our CMC team and other R&D members to continually refine the technology and manufacturing process for this class defining technology. If you have a knack for recombinant DNA cloning and mammalian cell culture, are meticulous and driven to achieve, this opportunity may be just what you are looking for.

The Research Technician will work along side senior researchers and project teams and participate in experiments in molecular biology and virology following established laboratory standard operating procedures (SOPs).  The incumbent is expected to prepare data/figures to report directly to senior research staff in support of multiple projects. Additional responsibilities will include inventory management; organize freezers; routine maintenance; calibration and troubleshooting on laboratory equipment.  We have an open, transparent and dynamic culture that embraces scientific excellence, integrity, urgency, partnerships with key stakeholders and continuous learning/improvements.

Experience & Qualifications:

  • MSc, BSc or community college diploma plus 2-3 years’ experience in an academic or industrial laboratory or combination of education and experience.
  • Expert in recombinant DNA methods and mammalian cell culture
  • Must have good analytical and problem-solving abilities
  • Self-starter with a strong work ethic and attention to detail
  • Knowledge and experience with standard software (e.g. LIMS, Microsoft Office Suite, Graphpad Prism)
  • Knowledge and commitment of Occupational Health and Safety Procedures in a laboratory. 

To Apply:

Please forward applications via email only to hr@turnstone.com including a cover letter and resume. In the e-mail subject line, please indicate the position title RESEARCH TECHNICIAN-Molecular Biology.

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency.  Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:

The position is located in Ottawa and reporting to the SVP, Discovery.  The position of Scientist/Immunologist is to manage all aspects of the discovery, validation and preclinical development to advance a novel neoantigen immunotherapy from the discovery phase into the clinic.  The incumbent will demonstrate his/her ability to participate in a highly matrixed and innovative research environment with a track record of translating basic research findings into novel therapeutic strategies that support clinical drug development.  He/she will contribute to the technical development and testing of a first-in-class personalized immunotherapy, meshing tumour genomics with individualized vaccine construction.  The position contributes both intellectually and experimentally as part of a multidisciplinary team with the development of strong cross-functional relationships being important for success.

Responsibilities:

  • Focused work in tumor and immune cell target identification/validation leading to innovative next generation biologics and modalities.
  • Utilize expertise to independently design, execute and analyze experiments using cellular and molecular immunological assays to investigate and uncover novel target biology and technologies to foster neoantigen targeted immunotherapy.
  • Effectively collaborate with other members of the company, including external collaborators and partners.
  • Prepare and present hypotheses, on-going progress reports, technical reports and future plans (including contributing to budgets strategic presentations).
  • Contribute to building a culture that embraces scientific excellence, integrity, urgency, partnerships with key stakeholders and continuous learning/improvements.

Experience & Qualifications:

  • Must hold a Ph.D. in biology/immunology/oncology/pharmacology or a related field with 4+ years of experience or an acceptable combination of education and experience.
  • Robust understanding of innate and adaptive immune systems is required.
  • Experience with in vivo models, isolation and culture of primary cells (both mouse and human).
  • A working knowledge of immune based in vitro assays, flow cytometry and common molecular techniques.
  • Experience in T cell function/differentiation/signaling/regulation, phenotypic analysis of inhibitory and costimulatory targets and pathways and/or neoantigen biology and vaccines is highly preferred.

To Apply:

Please forward applications via email only to hr@turnstone.com including a cover letter and resume. In the e-mail subject line, please indicate the position title SCIENTIST-IMMUNOLOGIST. Although not required, you are invited to include your salary expectations in your cover letter.

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency.  Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

 

Position Overview:

The position is located in Ottawa and reporting to the Group Leader/Sr. Scientist.

Our company’s technology is based around replicating oncolytic virus vaccines engineered to target tumours and launch massive tumour targeting immune responses.   Your role will be to join a team of molecular biologists and immunologists who engineer and test these nanomedicines for preclinical and clinical development.

The Vet Technician, is charged with conducting the bulk of animal procedures and conducts day-to-day monitoring of experimental animals.  The Vet Tech will provide specialized technical, pre-clinical and clinical services for a variety of research personnel including training.  Responsible for assisting end-users/Researchers with laboratory animal techniques as well as continuous re-training for reassignment and development purposes.  In compliance with the CCAC, CFIA and other regulatory guidelines, ensures ethical animal care throughout the facility.

Responsibilities:

  • Provides technical assistance and support to the immunology research group.
  • Administers oral & topical medications; subcutaneous, intraperitoneal and intravenous injections
  • Sample collection as required such as blood, urine, tissue samples
  • Administers, monitors & maintains anesthetics, administers analgesics
  • Collects data and maintains project records for assigned research projects
  • Maintains facility health surveillance program under Veterinary supervision; sample submission & record keeping of results
  • Clinical responsibility and assistance with surgeries, surgical monitoring and post-operative recovery.
  • Management of breeding colonies
  • Enable and support mouse identification and biopsies (ear notching, tail clipping)
  • Provision and training of animal handling and various technical procedures for all end-users/Researchers.
  • Monitors Study Protocol with end-user/Researchers and maintains ethical treatment of animals
  • Other duties as required

Experience & Qualifications:

  • Post-secondary graduate of a Veterinary Technician/Animal Health Technician program.
  • 3-5 years’ experience working in animal research in either an academic or biotech/pharma setting.
  • Must be a registered Laboratory Animal Technician with CALAS (e.g. Certified Veterinary Technician (CVT); Licensed Veterinary Technician (LVT); or a Registered Veterinary Technician (RVT)).
  • Working knowledge of CCAC guidelines and OMAFRA regulations is required.
  • Must have strong technical skills, attention to detail and excellent record keeping skills are essential
  • Must possess an excellent work ethic, maintain a professional attitude and maintain high standards to detail, being able to work independently and in a team environment with the ability to interact positively with other team members
  • Must be able to detect, analyze and resolve issues professionally as they arise
  • Solid background in animal husbandry and capable of maintaining mutant colonies.
  • Experience with processing Animal Use Protocols and previous membership on an Animal Care Committee is an asset.

 

To Apply:

Please forward applications via email only to hr@turnstone.com including a cover letter and resume. In the e-mail subject line, please indicate the position title VET TECHNICIAN.

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency.  Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:

Our company’s technology is based around replicating oncolytic virus vaccines engineered to target tumours and launch massive tumour targeting immune responses.  The core of this technology lies in the designing and building of these genetically constructed viruses.  Your role will be to join a team of molecular biologists who engineer these nanomedicines for preclinical and clinical development.  There will be additional opportunities to work with our CMC team and other R&D members to continually refine the technology and manufacturing process for this class defining technology. If you have a knack for recombinant DNA cloning and mammalian cell culture, are meticulous and driven to achieve, this opportunity may be just what you are looking for.  We have an open, transparent and dynamic culture that embraces scientific excellence, integrity, urgency, partnerships with key stakeholders and continuous learning/improvements.

Experience & Qualifications:

  • PhD, MSc or BSc in a related field and 3-5 years in an academic or industrial (biotech/pharma) laboratory or an equivalent combination of education and experience.
  • Expert in recombinant DNA methods and mammalian cell culture
  • Exercise independent judgement, initiative and decision-making in consultation with senior researchers to resolve matters relating to interpretation of test results
  • Good analytical and problem solving abilities with strong attention to detail
  • Knowledge and experience with standard software (e.g. Microsoft Office Suite, GraphPad Prism)
  • Knowledge and commitment to Occupational Health and Safety Procedures and Biosafety, Animal Handling Procedures in a laboratory

To Apply:

Please forward applications via email only to hr@turnstone.com including a cover letter and resume. In the e-mail subject line, please indicate the position title RESEARCH ASSOCIATE-Molecular Biology.

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next- generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:

Reporting to the Senior Director, Clinical Operations, the Clinical Project Manager (CPM) is responsible for the overall management and execution of operational activities involved in the planning, implementation, conduct and completion of clinical trials. This includes management of study deliverables, adherence to budget and timelines, and ongoing risk mitigation. The CPM leads cross functional clinical study teams (clinical monitoring, clinical science, data management, biostatistics, medical writing, medical affairs, regulatory affairs, and clinical QA) to ensure the project is completed on time, within budget, and with high quality.

Responsibilities:

  • Manage and coordinate all aspects of assigned clinical trials, North America and Global, to ensure they are conducted in accordance with established protocols, Company standards (SOPs), ICH/GCP and applicable jurisdiction regulations
  • Assists/leads the identification, evaluation and selection of external vendors (central lab, CROs, consultants/contractors, etc.)
  • Coordinates and assists in the CRO and vendor contracting process and performs ongoing vendor management to ensure deliverables and performance adhere to contract
  • Oversees, manages and reports on project activities, including scope, schedule, budget and risk associated with each assigned project
  • Identifies and tracks key study metrics in order to identify/anticipate issues (early) and conduct root-cause investigations for issue resolution and/or escalation (as needed)
  • Develops clinical trial timelines, tracks the overall study critical path and manages/oversees all study activities to ensure on-time study delivery
  • Reports study performance and timelines to senior management
  • Oversees the identification, selection and initiation of clinical sites
  • Oversees the development of required study plans and execution of those plans related to site monitoring, safety management, data management and biostatistics
  • Oversees development of CRFs, clinical and safety databases, and shell Tables, Figures and Listings
  • Plans, coordinates and conducts investigator meetings
  • Plans, coordinates and conducts Data Safety Monitoring Board (DSMB) meetings
  • With Medical Affairs, assesses trends in data including adverse events, protocol violations, etc
  • Coordinates and manages timely database freeze and database lock
  • Participates in data review meeting
  • Maintains the Trial Master File for each project and oversee the archival process
  • Assists the scientific staff in developing and reviewing protocols, investigator brochures, informed consent forms, clinical study reports and other scientific documents
  • Assists Regulatory Affairs as necessary for IND/CTA filing and other necessary compliance requirements

Experience & Qualifications:

  • BS in scientific discipline or pharmacy, RN, or BSN degree or equivalent combination of education and experience
  • Minimum 5 years of clinical trial/project management experience
  • Oncology background or experience preferred
  • Ability to travel approximately 20-50% based on study demands
  • Excellent working knowledge of GCP/ICH Guidelines
  • Ability to work effectively independently or as part of a team, remotely or in-office
  • Comfortable managing multiple projects and ability to adapt to changing priorities
  • Effective written communication skills and computer skills are required
  • Strong understanding of Clinical Development

 

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title CLINICAL PROJECT MANAGER.


Turnstone Biologics welcomes and encourages applications from people with disabilities.
Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next- generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:

We are seeking a creative and highly motivated Clinical Leader to be responsible for the oversight and execution of clinical assays. The Clinical Assay Director will report to the Vice-President, Translational Development and be based in either the New York or Ottawa offices. The Clinical Assay Director will be responsible for the development of assays for testing of clinical samples, including development of a companion diagnostic assay. The candidate will oversee clinical assay conduct, analyze results, write up and report results and interpretation to the scientific and clinical teams. The candidate will also advise on correlate sample testing during clinical trial design. The successful candidate will have experience synthesizing and facilitating key discussions on therapeutic product and companion diagnostic co-development.

Responsibilities:

  • Drive the implementation of the clinical diagnostic strategy for multiple therapeutics
  • Lead development of companion diagnostic in collaboration with appropriate vendors and other stakeholders
  • Select centralized testing vendors and assays to best investigate the clinical biomarkers and mechanism-of-action questions
  • Oversee implementation of clinical trial assays at centralized testing vendors
  • Remain up to date on new technologies, methods, and regulatory expectations
  • Perform data analysis of various assays, which could include virus plaque assays, RT-qPCR and RT-PCR, western blots, immunoassays (ICS, ELISPOT), among others
  • Draft reports for internal and external stakeholders
  • Review, summarize, document, and prepare data for databases and formal reports
  • Trend data on per patient and per group basis to discover meaningful correlations and trends
  • Draft regulatory documents for biomarker and companion diagnostics
  • Maintain knowledge of applicable regulatory requirements and relevant scientific/technical issues
  • Generate and maintain clinical SOPs to support technical work at sites
  • Manage contracts, budgets and timelines
  • Maintain involvement in a wide spectrum of R&D functions including evaluation of drug candidates and clinical biomarker research
  • Other projects and responsibilities as required

Experience & Qualifications:

  • BSc./MSc. or advanced science degree and at least 5-7 years of pharma/clinical research-related experience or equivalent combination of education and experience
  • Experience in development, outsourcing and validation of clinical assays
  • Excellent analytical, technical writing, and data management skills
  • Excellent working knowledge of Microsoft Office, including Word, Excel, PowerPoint, Outlook
  • Excellent written and oral communication skills
  • Strong ability to work closely with several disciplines within a small company, displaying innovative thinking, motivation, and accountability
  • Good planning and organizational skills
  • Able to multi-task, react, and adapt to changing priorities
  • Attention to detail
  • Well-developed interpersonal skills
  • Ability to travel as required
  • Companion diagnostic experience in oncology considered a strong asset
  • Knowledge in virology, oncology, and immunology

 

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title CLINICAL ASSAY DIRECTOR.


Turnstone Biologics welcomes and encourages applications from people with disabilities.
Accommodations are available on request for candidates taking part in all aspects of the selection
process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing CMC team that embraces being a learning organization with a sense of urgency, where CMC is a differentiator and enabler rather than a cost-center. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com or email info@turnstonebio.com.

 

What’s in it for you?

In this role, you will have the opportunity to develop, manage and drive the Quality Assurance systems for the multiple rationally designed and engineered live-viruses that constitute our platform technology of novel biotherapeutics to combat cancer. On the heels of a successful Series B financing, Turnstone’s CMC team is expanding to support the development of several parallel candidates towards the clinic.  Joining Turnstone at this early phase, will allow you to actively participate in developing a role designed just for you: one that leverages your expertise, while challenging you to develop new skills.  You will partner very closely with Quality Control, Analytical Development, and Manufacturing Operations teams, to successfully release final Drug Product, characterize product intermediates and processes, and enable stability and comparability studies. You will be required to manage key suppliers and have a close interaction with our contract research, manufacturing and testing organizations.  As a start-up biotech, the emphasis will be on establishing a phase-appropriate quality system that complies with FDA and Health Canada regulations. Once established, you will be a champion to ensure that quality is continuously improved.  This is a great learning opportunity that will include the oversight of the product platforms currently being manufactured for Phase 1 and 2 clinical trials, with a broad global regulatory reach (e.g., Health Canada, FDA, EMA, TGA) and line-of-sight to Phase 3/Pivotal clinical studies.   In parallel, you will have to be mindful and be prepared to incorporate the ever expanding discovery platform, and pipeline, that will need to scale and grow aggressively, to enable global early clinical-stage explorations.

 

How do you know if you’re the right fit?

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Thursday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

If you are interested in being part of the Quality Assurance of an early clinical-stage company, where you have the opportunity to learn about cutting edge products, processes, and methods while taking on a critical role within the Chemistry, Manufacturing and Controls team, then this role may be for you! Your role will partner closely with all facets of the CMC team, allowing you to understand the product and processes as well as the quality system within which we work.  You’ll be an integral part of the product release group, working closely with Quality Control to ensure the highest quality of products are released for use in our clinical trials.  You’ll interface directly, on an almost daily basis, with critical vendors to assess their ability for meeting quality system requirements. You’ll have experience working with some or all the following, as they relate to Quality Assurance:

  • Review and approval of GMP-related CMO documentation, including, as appropriate, Master Batch Records, SOPs, material specifications, Batch Production Records (field copies), Investigations, Deviations and Corrective Actions.
  • Product review and release for GMP products.
  • Issuance of certificates of analysis for all GMP products.
  • Support of CMO deviation investigations and review and approval of CMO deviation reports.
  • Management of vendor and sub-contractor audits and approval of vendors.
  • Establishing and management of quality-related SOPs.
  • Quality systems development and management (e.g. change control, deviation, corrective actions, OOS/OOT investigations, document control and training).

 

The details

This role is best suited for a Quality Assurance professional with experience working in the biotechnology or pharmaceutical industry, with at least 8 years of Quality Assurance experience of which 3 years is at the management level.  Of course, if you have significantly more experience we’re very excited to consider how we could design the scope of work together so you’re challenged and continuously feel like you’re growing – that’s what we do! You’ve likely achieved a minimum a Bachelor’s degree in a relevant scientific discipline and have supplemented this knowledge with experience and courses in GMP and Quality Assurance principles. Your knowledge in virology, oncology and/or immunology would be an asset. You are looking to use your knowledge in a meaningful and impactful way, while also learning about new methods, products, and processes.  You are not hesitant to roll-up your sleeves and drive a project forward, while also being able to handle a large to-do list by prioritizing and discussing creative solutions with your colleagues.  You are eager to learn and have a low threshold for asking questions.  You have a tremendous attention for detail and are very meticulous in your work.  You have demonstrated the ability to manage both small and large projects, multi-tasking effectively, and having an external presence that is professional, collaborative, and influential.  You will need to travel on occasion to our various CRO and CMOs, and also visit our Ottawa and NYC offices often to stay connected, productive, and excited. This role will report to the Associate Director of Quality Assurance at Turnstone. Based on a mutual discussion of fit, the successful candidate(s) will reside at either the Ottawa or New York office location.

 

To Apply:

Please forward applications via email only to hr@turnstone.com including a cover letter and resume. In the e-mail subject line, please indicate the position title Quality Assurance Manager.

Turnstone Biologics welcomes and encourages applications from people with disabilities.Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing Chemistry, Manufacturing, and Control (CMC) team that embraces being a learning organization with a sense of urgency, where CMC is a differentiator and enabler rather than a cost-center. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com or email info@turnstonebio.com.

What’s in it for you?

In this role, you will have the opportunity to supervise and drive the Quality Control testing of multiple rationally designed and engineered live-viruses that constitute our platform technology of novel biotherapeutics to combat cancer. On the heels of a successful Series B financing, Turnstone’s CMC team is expanding to support the development of several parallel candidates towards the clinic. Joining Turnstone at this early phase, will allow you to actively participate in developing a role designed just for you: one that leverages your expertise, while challenging you to develop new skills. This role will include partnering very closely with Quality Assurance, Analytical Development, and Manufacturing Operations teams, to successfully release final Drug Product, characterize product intermediates and processes, and enable stability and comparability studies. This role will require a close interaction and management of our analytical vendors across the world to ensure timely, reliable, scientifically sound, and quality results are generated. Assay qualification and validation efforts, as well as stability studies, have already begun but will need further development and guidance. This is a great learning opportunity to work side-by-side with Analytical Development to prepare our assays for late-stage clinical development, with a close eye towards preparing for commercial launch. In parallel, we have an ever expanding discovery platform and pipeline that will need to scale and grow aggressively, to enable global early clinical-stage explorations.

How do you know if you’re the right fit?

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Thursday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

If you are interested in the CMC Quality Control of an early clinical-stage company, where you have the opportunity to learn about cutting edge products, processes, and methods while taking on a critical role within the Quality and Analytical Team, then this role may be for you! Your role will partner closely with most facets of the CMC team, allowing you to understand the product and process as well as the quality system within which we work. You’ll be an integral part of the product release group, working closely with Quality Assurance to ensure the highest quality of products are released for use in our clinical trials. You’ll interface directly with analytical vendors to ensure a timely and accurate execution of our tests, and to investigate and resolve suspect results. You’ll have experience working with some or all the following, as they relate to Quality Control, testing, and stability:

  • Live-virus methods such as titering, genome quantitation by qPCR, neutralizing antibody assays, plaque forming unit methods, etc
  • Compendial product testing as outlined in USP and/or EP (including, but not limited to, endotoxin, sterility, mycoplasma, in vivo and in vitro adventitious agents testing)
  • Quality Control regulations and guidances from FDA, Health Canada, WHO, etc
  • Reviewing raw data and reports for scientific accuracy, completeness, adherence to protocols, etc
  • Assay qualification and validation according to principles in ICH Q2
  • Working closely with external CROs and vendors to manage testing and suspect result
    investigations
  • Quality systems (change control, deviations, corrective and preventive actions, OOS/OOT investigations, document control)

The details

This role is best suited for a scientist with experience working in a biotech analytical lab, with both hands-on and at least 3 years of Quality Control analyst experience. Of course, if you have significantly more experience we’re super excited to consider how we could design the scope of work together so you’re challenged and continuously feel like you’re growing – that’s what we do! You’ve likely achieved either a Masters or PhD in a relevant scientific discipline and have supplemented this knowledge with experience and courses in GMP and Quality Control principles. You are looking to use your knowledge in a meaningful and impactful way, while also learning about new methods, products, and processes. You are not hesitant to roll-up your sleeves and drive a project forward, while also being able to handle a large to-do list by prioritizing and discussing creative solutions with your colleagues. You are eager to learn and have a low threshold for asking questions. You have a tremendous attention for detail and are very meticulous in your work. You have demonstrated the ability to manage both small and large projects, multi-tasking effectively, and having an external presence that is professional, collaborative, and influential. You will need to travel on occasion to our various CRO and CDMOs, and also visit our Ottawa and NYC offices often to stay connected, productive, and excited. This role will report to the Group Leader of Analytical Development and Quality Control at Turnstone. Based on a mutual discussion of fit, the successful candidate(s) will reside at either the Ottawa or New York office location.

 

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title QUALITY CONTROL ANALYST.


Turnstone Biologics welcomes and encourages applications from people with disabilities.
Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing CMC team that embraces being a learning organization with a sense of urgency, where CMC is a differentiator and enabler rather than a cost-center. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com or email info@turnstonebio.com.

What’s in it for you?

In this role, you will have the opportunity to own and drive the scientific and technical development of analytical assays for release and characterization testing of our live-virus platform technology of novel biotherapeutics to combat cancer. On the heels of a successful Series B financing, Turnstone’s CMC team is expanding to support the development of several parallel candidates towards the clinic. Joining Turnstone at this early phase, will allow you to actively participate in developing a role designed just for you: one that leverages your expertise, while challenging you to develop new skills. This role will include partnering very closely with our Manufacturing Sciences & Technology group and Quality Control team, to generate assays that are relevant and cutting edge. This role will require a close interaction and management of our analytical vendors across the world to ensure timely, scientifically sound, and quality results are generated. Assay qualification and validation efforts have already begun but will need further development and guidance. This is a great learning opportunity to work hand-in-glove with Quality Control to prepare our assays for late-stage clinical development, with line-of-sight towards commercial launch, while also enabling an explosive early-stage clinical pipeline.

How do you know if you’re the right fit?

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Tuesday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

If you are interested in managing and driving analytical development for an early clinical-stage company, where you take on a scientific and sometimes vendor management role, while rolling up your sleeves, then this role may be for you! Your role will partner closely with Quality Control and Manufacturing Sciences & Technology to understand the product and processes as well as the quality system within which we work.

You will interface directly with analytical vendors to drive the development of virological, biophysical, biochemical, and molecular assays to reliably and accurately characterize our product. These assays will support the GMP release and characterization of drug product destined for the clinic, as well as support product and process characterization, comparability, stability, and other studies within the CMC team needs. You’ll have experience working with some or all the following, as they relate to analytical development and methods:

  • Live-virus methods such as titering, genome quantitation by qPCR, neutralizing antibody assays, plaque forming unit assays, etc
  • Biophysical particle measurements such as HPLC, DLS, and nanosight
  • Assay development and reporting
  • Assay qualification and validation according to principles in ICH Q2
  • Working closely with external CROs and vendors to drive projects to completion in a timely and scientifically sound manner
  • Quality systems (change control, deviations, corrective and preventive actions, document control)

The details

This role is best suited for a scientist with experience working in a biotech analytical lab, with both hands-on and preferably 5 or more years of leading complex projects, perhaps including the coaching and supervising of either a team you were directly responsible for, or the team of an external vendor. You’ve likely achieved either a Masters or PhD in a relevant scientific discipline and are looking to use your knowledge in a meaningful and impactful way, while also learning about new methods, products, and processes. You are not hesitant to roll-up your sleeves and drive a project forward, while also being able to handle a large to-do list by prioritizing and discussing creative solutions with your colleagues. You have demonstrated the ability to manage both small and large projects, multi-tasking effectively, and having an external presence that is professional, collaborative, and influential. You will need to travel on occasion to our various vendors, and also visit our Ottawa and NYC offices often to stay connected, productive, and excited. This role will report to the Group Leader of Analytical Development and Quality Control at Turnstone. Based on a mutual discussion of fit, the successful candidate(s) will reside at either the Ottawa or New York office location.

 

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title ANALYTICAL DEVELOPMENT SCIENTIST.


Turnstone Biologics welcomes and encourages applications from people with disabilities.
Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in- class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing CMC team that embraces being a learning organization with a sense of urgency, where CMC is a differentiator and enabler rather than a cost-center. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com or email info@turnstonebio.com.

What’s in it for you?

In this role, you will have the opportunity to help operationalize and drive the strategy, and process development efforts behind a suite of viral and non-viral biotherapeutics. On the heels of a successful Series B financing, Turnstone’s CMC team is expanding to support the development of several parallel candidates towards the clinic. Joining Turnstone at this early phase, will allow you to actively participate in developing a role designed just for you. One that leverages your expertise, while challenging you to develop new skills. As a small team, all of our development is currently contracted to external partners, who have dedicated teams with deep knowledge in their space. You will work with these partners to manage the scientific direction of Turnstone’s platform technology with a scope that is large in its complexity, and size. As Turnstone moves to expand capabilities and establish in-house development labs, you will have the ability to hire and mentor staff and build processes unique to our mission. At Turnstone, you will be immersed in a learning organization, where everyday you are faced with challenges that require a unique solution. Our work is fast-paced, and requires cross-functional interaction at every turn. Regular insights from the clinical team provides for the best motivation, and makes our ‘roll-up your sleeves’ mentality all the more worthwhile.

How do you know if you’re the right fit?

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Wednesday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

The details

This role is best suited for a scientist/engineer with a Bachelor’s of Science, and advanced degree (MSc or PhD). You will be accountable for developing methods, processes and assessing equipment to support upstream and downstream drug substance development including but not limited to media development, cell culture, perfusion modeling, virus infection/harvest, clarification, filtration, ultrafiltration, and chromatography. The role will likely require a minimum of 5 years of industry experience (MSc) or 3 years of industry experience (PhD). You will need to travel monthly to our various vendors to lead the scientific progress, and also visit our Ottawa and NYC offices often to stay connected, productive, and excited. This role will report to the Leader of the Manufacturing Sciences and Technology group, within the CMC department. Based on a mutual discussion of fit, the successful candidate(s) will reside at either the Ottawa or New York office location.

 

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title PROCESS DEVELOPMENT SCIENTIST/ENGINEER.


Turnstone Biologics welcomes and encourages applications from people with disabilities.
Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing CMC team that embraces being a learning organization with a sense of urgency, where CMC is a differentiator and enabler rather than a cost-center. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com or email info@turnstonebio.com.

What’s in it for you?

In this role, you will have the opportunity to design, build, implement, and operate a clinical manufacturing supply chain for our suite of novel biotherapeutics to combat cancer. On the heels of a successful Series B financing, Turnstone’s CMC team is expanding to support the development of several parallel candidates towards the clinic. Joining Turnstone at this early phase, will allow you to actively participate in developing a role designed just for you. One that leverages your expertise, while challenging you to develop new skills. This role will include driving a raw materials inventory, product inventory, distribution, and warehousing, all while serving as the primary contact amongst our network of external products to move product from R&D to GMP manufacturing to the patients we serve. Fortunately, the Turnstone CMC team has already initiated two clinical studies with Health Canada, so you’re not starting from zero, but we need someone to really own, drive, and lead our supply chain, showing us how the professionals do it, all while remaining flexible, dynamic, working with a sense of urgency, and innovation. This is definitely a ‘roll up your sleeves’ role, but we’re hiring a leader that is setting the foundation for mature, manufacturing supply chain capable of supporting late-stage (Ph3/Pivotal) clinical studies, and commercial launch – you will bring the vision.

How do you know if you’re the right fit?

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Wednesday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

If you are interested in leading critical procurement, warehousing, and logistics operations under highly fluid, rapidly changing conditions – this job is for you! You’ll enjoy a diverse role as you partner closely with various groups such as Manufacturing Sciences & Technology, Analytical Development and Quality Control, Manufacturing Operations, Quality Assurance, and Clinical Operations to ensure all types of materials are procured, appropriately distributed, and stored in a compliant manner. In addition, you’ll partner closely with CDMOs, CROs, and CTOs to manage relationships, negotiate pricing and terms, and conquer challenges.  You’ll use your well-developed communication skills in monitoring and enforcing requirements with all vendors and as you work with internal stakeholders at all levels.  You’ll have experience working with some or all of the following, as they relate to supply chain management:

  • Inventory and Enterprise Resource Management systems
  • Procurement systems
  • Critical logistics, including import/export, cold chain, and time-sensitive shipping
  • External vendors, including critical material suppliers and contract development/manufacturing organizations (CDMOs), contract testing organizations (CTOs), and contract research organizations (CROs)
  • Warehouse materials management, including receipt, storage, issuance, and shipping, preferably at multiple sites
  • Quality systems (change control, deviations, corrective and preventive actions, document control)
  • Experience with Lean principles, Kanban, Just-In-Time logistics, Continuous Improvement, etc. are a plus. This is definitely a ‘hands-on’ role with incredible upside opportunities.

The details

This role is best suited for supply chain professionals with significant experience developing and managing a GMP clinical manufacturing supply chain. You’ve likely studied supply chain and logistics, or perhaps were a classically trained scientist/engineer and supplemented your education to be successful. You must be able to demonstate both leadership and a willingness to be a ‘do-er’, likely having 5 years or more experience in GMP manufacturing supply chain and logistics. You have demonstrated the ability to manage both small and large projects, multi-tasking effectively, and having an external presence that is professional, collaborative, and influential. You will need to travel monthly to our various vendors, and also visit our Ottawa and NYC offices often to stay connected, productive, and excited. This role will report to the Vice President of CMC/Manufacturing at Turnstone and be a part of the CMC Leadership Team. Based on a mutual discussion of fit, the successful candidate(s) will reside at either the Ottawa or New York office location.

 

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title MANUFACTURING SUPPLY CHAIN LEADER.


Turnstone Biologics welcomes and encourages applications from people with disabilities.
Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing CMC team that embraces being a learning organization with a sense of urgency, where CMC is a differentiator and enabler rather than a cost-center. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com or email info@turnstonebio.com.

What’s in it for you?

In this role, you will have the opportunity to lead, drive, and own GMP clinical manufacturing operations for a suite of novel biotherapeutics to combat cancer. On the heels of a successful Series B financing, Turnstone’s CMC team is expanding to support the development of several parallel candidates towards the clinic. Joining Turnstone at this early phase, will allow you to actively participate in developing a role designed just for you: one that leverages your expertise, while challenging you to develop new skills. This role will include partnering very closely with our Manufacturing Sciences & Technology group to understand the Drug Substance and Drug Product processes, with a collaborative effort to successfully transfer those processes to our network of CDMOs. Once transferred, you will lead all manufacturing operations including batch production record management, manufacturing schedule, providing ‘on-the-floor’ review and support as required, and overcoming challenges related to manufacturing deviations. You are truly the relationship manager and interface between Turnstone Biologics and our Manufacturing partners, representing us with the professionalism, creativity, and collaborative spirit that embodies who we are. Fortunately, the Turnstone CMC team has already initiated two clinical studies with Health Canada, so you’re not starting from zero, but we need someone to really own, drive, and lead our manufacturing operations, showing us how the professionals do it, all while remaining flexible, dynamic, working with a sense of urgency, and innovation. This is definitely a ‘roll up your sleeves’ role, but we’re hiring a leader that is setting the foundation for mature, manufacturing operations capable of supporting late-stage (Ph3/Pivotal) clinical studies, and commercial launch – you will bring the vision.

How do you know if you’re the right fit?

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Wednesday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you. If you are interested in leading, driving, and owning manufacturing operations for an early clinical-stage company, where you need to both provide vision and strategy while rolling up your sleeves, then this role may be for you! You’ll enjoy a diverse role as you partner closely with various groups such as Manufacturing Sciences & Technology, Analytical Development and Quality Control, Supply Chain, Quality Assurance, and Clinical Operations. You will have led GMP manufacturing operations for complex biopharmaceuticals, ideally live-virus vaccines or similar, and will have both clinical and commercial manufacturing experience. You’ll use your well-developed communication skills and ability to influence and partner very closely with our networks of CDMOs and internal stakeholders at all levels.  You’ll have experience working with some or all the following, as they relate to manufacturing operations:

  • Live-virus manufacturing experience, ideally hands-on as well as leading broader manufacturing teams or projects partners with external vendors
  • Very well versed in GMPs with a clear understading of ‘phase-appropriateness’ as well as an appreciation for continuous improvement
  • A relationship manager and primary interface for external vendors, including critical material suppliers and contract development/manufacturing organizations (CDMOs), contract testing organizations (CTOs), and contract research organizations (CROs)
  • Quality systems (change control, deviations, corrective and preventive actions, document control)
  • Experience with Lean principles, Kanban, Continuous Improvement, etc. are a plus. This is definitely a ‘hands-on’ role with incredible upside opportunities.

The details

This role is best suited for manufacturing professionals with significant experience developing and managing a GMP manufacturing operation. You’re likely a classically trained scientist/engineer and supplemented your education to be successful, particularly with training in operational excellence and manufacturing. You must be able to demonstate both leadership and a willingness to be a ‘do-er’, likely having 5 years or more experience in GMP clinical or commercial manufacturing. You have demonstrated the ability to manage both small and large projects, multi-tasking effectively, and having an external presence that is professional, collaborative, and influential. You will need to travel monthly to our various vendors, and also visit our Ottawa and NYC offices often to stay connected, productive, and excited. This role will report to the Vice President of CMC/Manufacturing at Turnstone and be a part of the CMC Leadership Team. Based on a mutual discussion of fit, the successful candidate(s) will reside at either the Ottawa or New York office location.

 

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title MANUFACTURING OPERATIONS LEADER.


Turnstone Biologics welcomes and encourages applications from people with disabilities.
Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Notice to Recruiters: Turnstone Biologics values our recruiting partnerships, but to protect the interest of all parties, we do not accept unsolicited resumes from recruiters. All recruiting is managed through our human resources department.

Contact

Ottawa

787 Bank Street, 2nd Floor
Ottawa, Ontario K1S 3V5
(613) 421-8930

New York City

110 East 25th Street
New York, New York 10010
(613) 421-8930

General

Please contact us with any questions
or comments.

Info@turnstonebio.com

Media

Please contact Pure Communications
for any media inquiries.

Turnstone@W2OGroup.com